Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Poznan
Clinical trial register · Poland

Clinical Trials in Poznan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 95 Lodz 80 Krakow 70 Poznan 67 Gdansk 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Merck Sharp & Dohme LLC43 Poznan University of Medical Sciences35 Janssen Research & Development, LLC27 Bristol-Myers Squibb23 Clear sponsor filter
Site location
Warsaw95 Lodz80 Krakow70 Poznan67 Gdansk59
All 81 locations
Target enrolment
to

Trials with a site in Poznan

67 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
AstraZeneca
Phase 3
1,330
Gdansk, Koszalin, Krakow, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2026-09-15
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bialystok, Częstochowa, Gdynia, Katowice, Krakow, Poznan, Przemyśl, Radzionków
2026-08-24
Recruiting
AstraZeneca
Phase 3
1,500
Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan
2026-08-19
Recruiting
AstraZeneca
Phase 3
915
Gdansk, Koszalin, Poznan, Siedlce, Skórzewo, Wroclaw
2026-07-16
Recruiting
AstraZeneca
Phase 3
600
Bialystok, Częstochowa, Kielce, Krakow, Lodz, Poznan, Radom, Warsaw
2026-07-08
Recruiting
AstraZeneca
Phase 3
2,000
Bialystok, Częstochowa, Kielce, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Bialystok, Krakow, Lodz, Lublin, Poznan, Radom, Warsaw
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Bialystok, Bydgoszcz, Kielce, Krakow, Lodz, Lublin, Poznan, Radom
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Gdansk, Gliwice, Kielce, Lublin, Poznan, Wroclaw
2026-06-26
Recruiting
Ravulizumab Outcomes in Polish Patients With aHUS
NCT07399730Atypical Hemolytic Uremic Syndrome
DrugRavulizumab
AstraZeneca
Observational
80
Gdansk, Katowice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2026-06-24
Recruiting
AstraZeneca
Phase 3
150
Gdansk, Konin, Krakow, Lodz, Lublin, Poznan, Przemyśl, Wroclaw
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bialystok, Krakow, Lodz, Poznan, Rzeszów, Warsaw
2026-06-11
Recruiting
AstraZeneca
Observational
2,150
Lublin, Krakow, Radom, Bialystok, Częstochowa, Poznan, Warsaw, Lodz
2026-05-06
Recruiting
AstraZeneca
Phase 3
508
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
2026-02-23
Recruiting
AstraZeneca
Phase 3
400
Lodz, Olsztyn, Poznan, Warsaw
2025-10-31
Recruiting
AstraZeneca
Phase 3
700
Gdynia, Gliwice, Koszalin, Krakow, Piotrkow Trybunalski, Poznan, Rzeszów, Warsaw
2025-08-06
Recruiting
AstraZeneca
Observational
50
Bydgoszcz, Gdansk, Katowice, Krakow, L DZ, Lublin, Poznan, Szczecin
2025-05-15
Recruiting
AstraZeneca
Phase 3
600
Bialystok, Gdansk, Lodz, Poznan, Siedlce, Szczecin
2025-03-27
Active, closed
AstraZeneca
Observational
105
Bydgoszcz, Bytom, Gdansk, Katowice, Krakow, Lodz, Lublin, Poznan
2025-02-28
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
Krakow, Poznan
2025-02-04
Recruiting
AstraZeneca
Phase 3
1,160
Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Bialystok, Biała Podlaska, Bydgoszcz, Bystra, Lodz, Lublin, Poznan, Warsaw
2024-11-18
Active, closed
AstraZeneca
Phase 3
768
Katowice, Krakow, Lodz, Olsztyn, Poznan
2024-10-04
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Sopot, Warsaw, Wroclaw
2024-08-28
Recruiting
AstraZeneca
Phase 3
788
Biała Podlaska, Koszalin, Lodz, Lublin, Poznan, Radom, Warsaw
2024-08-01
Recruiting
AstraZeneca
Phase 3
240
Bialystok, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2024-06-20
Recruiting
AstraZeneca
Phase 3
582
Bystra, Olsztyn, Poznan, Warsaw
2024-04-29
Recruiting
AstraZeneca
Phase 3
675
Olsztyn, Poznan, Przemyśl, Warsaw
2024-04-11
Active, closed
AstraZeneca
Phase 3
2,554
Chrzanów, Gdynia, Krakow, Lodz, Lublin, Olsztyn, Poznan, Rzeszów
2024-03-29
Active, closed
AstraZeneca
Phase 3
1,898
Bydgoszcz, Koszalin, Poznan, Rzeszów, Warsaw, Wroclaw
2023-11-21
Active, closed
AstraZeneca
Phase 3
863
Bystra, Olsztyn, Poznan, Warsaw
2023-11-09
Active, closed
AstraZeneca
Phase 3
1,835
Chrzanów, Krakow, Lodz, Poznan, Radom, Rzeszów, Szczecin, Warsaw
2023-11-07
Active, closed
AstraZeneca
Phase 3
895
Lublin, Poznan, Przemyśl, Radom, Warsaw
2023-10-24
Recruiting
AstraZeneca
Phase 3
800
Bialystok, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
2023-09-22
Recruiting
AstraZeneca
Phase 3
4,300
Bialystok, Grudziądz, Koszalin, Lodz, Lublin, Opole, Poznan, Racibórz
2023-03-31
Active, closed
AstraZeneca
Phase 3
1,350
Bydgoszcz, Bystra, Grudziądz, Kielce, Koszalin, Olsztyn, Poznan, Przemyśl
2022-12-29
Active, closed
AstraZeneca
Phase 3
594
Gdansk, Krakow, Poznan, Skórzewo
2022-09-15
Recruiting
AstraZeneca
Phase 2
454
Gliwice, Krakow, Lodz, Poznan, Warsaw
2022-09-06
Active, closed
AstraZeneca
Phase 2
194
Brzozów, Gdansk, Krakow, Lodz, Poznan, Warsaw
2022-08-11
Active, closed
AstraZeneca
Phase 3
644
Bialystok, Bydgoszcz, Lodz, Poznan, Warsaw, Wroclaw
2022-05-16
Active, closed
AstraZeneca
Phase 3
390
Poznan, Warsaw
2022-02-21
Active, closed
AstraZeneca
Phase 3
363
Lodz, Olsztyn, Opole, Poznan, Rzeszów
2022-02-15
Active, closed
AstraZeneca
Phase 3
1,051
Bydgoszcz, Gdansk, Koszalin, Poznan, Siedlce, Tomaszów Mazowiecki, Warsaw
2022-02-07
Active, closed
AstraZeneca
Phase 3
148
Gdansk, Gdynia, Krakow, Otwock, Poznan
2021-10-28
Active, closed
AstraZeneca
Phase 3
315
Bydgoszcz, Gdynia, Koszalin, Lodz, Poznan, Rzeszów, Tomaszów Mazowiecki, Warsaw
2021-06-30
Active, closed
AstraZeneca
Phase 2
31
Bydgoszcz, Olsztyn, Poznan
2021-02-23
Active, closed
AstraZeneca
Phase 3
1,371
Gdynia, Konin, Koszalin, Lodz, Lublin, Olsztyn, Poznan
2021-01-28
Active, closed
AstraZeneca
Phase 3
957
Bialystok, Gdansk, Krakow, Lodz, Poznan, Warsaw
2020-11-17
Active, closed
AstraZeneca
Phase 3
370
Bialystok, Bydgoszcz, Poznan
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Bydgoszcz, Gdansk, Krakow, Poznan, Warsaw
2020-08-18
Active, closed
AstraZeneca
Phase 3
185
Bialystok, Grzepnica, Lublin, Olsztyn, Poznan
2020-08-04
Active, closed
AstraZeneca
Phase 3
1,012
Bydgoszcz, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Rzeszów, Torun
2020-07-13
Active, closed
AstraZeneca
Phase 3
923
Bydgoszcz, Konin, Poznan, Racibórz, Radom, Tomaszów Mazowiecki, Warsaw, Wroclaw
2019-06-25
Active, closed
AstraZeneca
Phase 3
810
Gdansk, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2019-04-16
Active, closed
AstraZeneca
Phase 2
401
Bialystok, Lodz, Poznan, Prabuty
2018-12-21
Active, closed
AstraZeneca
Phase 3
407
Bialystok, Gdansk, Poznan, Tomaszów Mazowiecki, Warsaw
2018-11-27
Active, closed
AstraZeneca
Phase 3
1,063
Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Ostrołęka, Poznan
2018-11-16
Active, closed
AstraZeneca
Phase 3
730
Gdansk, Olsztyn, Poznan, Tomaszów Mazowiecki, Warsaw, Wroclaw
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,246
Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Poznan, Radom
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,018
Bialystok, Gdansk, Grudziądz, Koszalin, Piotrkow Trybunalski, Poznan, Warsaw, Wroclaw
2018-05-14
Active, closed
AstraZeneca
Phase 2
273
Dąbrowa Górnicza, Gdansk, Gdynia, Grzepnica, Krakow, Lodz, Olsztyn, Poznan
2018-03-07
Active, closed
AstraZeneca
Phase 3
953
Bydgoszcz, Kielce, Krakow, Lodz, Mrozy, Olsztyn, Poznan, Warsaw
2015-11-03
Active, closed
AstraZeneca
Phase 3
682
Krakow, Lodz, Otwock, Poznan, Racibórz, Warsaw, Wieliszew
2015-10-21
Active, closed
AstraZeneca
Phase 1
344
Gdansk, Krakow, Olsztyn, Poznan, Warsaw
2014-08-05
Active, closed
AstraZeneca
Phase 3
1,837
Gdansk, Grzepnica, Lodz, Olsztyn, Poznan, Warsaw
2014-04-22
Active, closed
AstraZeneca
Phase 3
736
Bialystok, Lodz, Poznan
2005-02-13
Rows per page Showing 1–67 of 67
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 October 2026. https://priyalifescience.com/clinical-trials-poland/city/poznan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 67 of those studies with a site in Poznan that also match the filters currently applied.

How many clinical trials are recruiting in Poznan?

29 of the 67 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 38 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Poznan), 67 studies
PhaseStudiesRecruitingShare
Phase 3532379.1%
Phase 28211.9%
Observational436%
Phase 1101.5%
Phase 4111.5%

Most active sponsors

Lead sponsors with the most studies (Poznan)
Lead sponsorStudiesRecruiting
AstraZeneca6729
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.